Subtype
Malignant Urinary System Neoplasm
CI-CAN-00001187Explore in graph →
888 active trials28 approved drugs109 evidence items
- NCIt
- C9297
Loading cancer entity…
Subtype
CI-CAN-00001187Explore in graph →
Clinical trials
3,853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (556)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07505615 | A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer(VG-INFUSE Tria) | completed | Phase 1 / Phase 2 | 20 | Ding-Wei YeOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07506057 | Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy(SHIELD) | recruiting | Phase 2 | 20 | Xiujuan QuOTHER |
| 1 |
| Apr 1, 2026 |
| clinicaltrials |
| NCT02555748 | Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma(SUP-R) | completed | Phase 4 | 47 | Institut Claudius RegaudOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07502716 | Compassionate Use of Ubamatamab | available | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Mar 31, 2026 | clinicaltrials |
| NCT07503795 | Outcomes of Definitive Radiotherapy for Bladder Cancer | not yet recruiting | — | 300 | Sohag UniversityOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03786796 | Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations(ORCHID) | recruiting | Phase 2 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06453642 | Evaluation of a Simple-Prep Controlled Embolic(GPX) | active not recruiting | N/A | 114 | Fluidx Medical Technology, Inc.INDUSTRY | 3 | Mar 30, 2026 | clinicaltrials |
| NCT06704191 | In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial | recruiting | Phase 1 / Phase 2 | 40 | Mayo ClinicOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07420517 | Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer(DutaBCa-1) | recruiting | Phase 2 | 95 | Paul TorenOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07500805 | UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma | not yet recruiting | Phase 1 | 21 | UTC Therapeutics Inc.INDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07500831 | Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma | not yet recruiting | N/A | 43 | Qilu Hospital of Shandong UniversityOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 115 | SOTIO Biotech AGINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT05226117 | Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer | completed | Phase 2 | 44 | IRCCS San RaffaeleOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06800963 | ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG | recruiting | Phase 1 / Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07494435 | Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC | not yet recruiting | Phase 2 | 230 | Zhejiang Haichang Biotech Co., Ltd.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07497958 | Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy | not yet recruiting | N/A | 174 | Sun Yat-sen UniversityOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05024214 | Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06447064 | Cancer Loyalty Card Study 2 (CLOCS-2)((CLOCS-2)) | recruiting | — | 2,900 | Imperial College LondonOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07492225 | Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial | active not recruiting | Phase 2 | 120 | Changhai HospitalOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07492628 | Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma(DUET-UC-NK) | recruiting | Phase 1 | 42 | Beijing BiotechINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07470840 | SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma | not yet recruiting | Phase 2 | 27 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 24, 2026 | clinicaltrials |
| NCT03091660 | S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer | active not recruiting | Phase 3 | 1,000 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06580938 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer | terminated | Phase 1 | 4 | PfizerINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07488533 | Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma | active not recruiting | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07488572 | Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study | enrolling by invitation | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT02690558 | Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy | completed | Phase 2 | 39 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors | terminated | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04113603 | Diagnostic Values of Urothelial Carcinomas: Single-bolus Versus Split-bolus Computed Tomography Urography | active not recruiting | N/A | 352 | Chang Gung Memorial HospitalOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04637594 | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy(IMAGINE) | active not recruiting | Phase 3 | 3 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04904302 | Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer | terminated | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05037279 | Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)(EVER) | recruiting | Phase 3 | 540 | Verity Pharmaceuticals Inc.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06721260 | Metabolism Evaluation Through Resting Indirect Calorimetry in Bladder Cancer (METRICS)(METRICS) | recruiting | — | 30 | University of Kansas Medical CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06882486 | Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic Therapy(NAMECAR) | recruiting | N/A | 60 | Institut Paoli-CalmettesOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07397611 | Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC | recruiting | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT03185039 | Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents | active not recruiting | N/A | 50 | Institut Paoli-CalmettesOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04055311 | Recovery Support for Bladder Cancer Patients and Caregivers | completed | N/A | 174 | Northwell HealthOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04338269 | A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment(CONTACT-03) | terminated | Phase 3 | 522 | Hoffmann-La RocheINDUSTRY | 15 | Mar 19, 2026 | clinicaltrials |
| NCT04960059 | NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts | completed | — | 24 | The Christie NHS Foundation TrustOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04970472 | Bio Clinical Collection of Urothelial Carcinoma(MicroBlad) | recruiting | — | 1,000 | University Hospital, ToulouseOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05923190 | Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma | active not recruiting | Phase 2 | 60 | Fox Chase Cancer CenterOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06072027 | Evaluation of VISIOCYT Bladder Cytology in Real Life(VISIOCYT2) | completed | — | 701 | Institut Paoli-CalmettesOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07004426 | Symptomatic and Incidental RCC Detection(KIDCaD) | completed | — | 1,000 | Charles University, Czech RepublicOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04007744 | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 36 | Mayo ClinicOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06307704 | Lung US for PEEP Optimization in Robotic Radical Prostatectomy or Cystectomy Patients | active not recruiting | N/A | 88 | Nazmy Edward SeifOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06408597 | Mannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or Cystectomy | active not recruiting | N/A | 90 | Nazmy Edward SeifOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07481123 | COMPARISON OF OBTURATOR NERVE BLOCK TECHNIQUES IN TURBT | completed | N/A | 60 | Yavuz SaygılıOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05738694 | Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma | recruiting | Phase 3 | 298 | ZHOU FANGJIANOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05888532 | 64Cu-GRIP B in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 91 | Rahul AggarwalOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05102110 | Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.(ORI-EGI-03) | recruiting | — | 450 | Origin SciencesINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 1, 2026source: clinicaltrials